Eupraxia Pharmaceuticals Reports Positive Symptom Data from Highest Dose Cohort in RESOLVE Trial for Eosinophilic Esophagitis Treatment

Eupraxia Pharmaceuticals reported six-month symptom data from its ongoing Phase 1b/2a RESOLVE trial in eosinophilic esophagitis. Patients in the highest dose cohort (n=3) had an average reduction of 4 points in their symptom scores compared to baseline. EP-104GI was well-tolerated, with no Serious Adverse Events reported in 31 patients and over 220 patient-months of follow-up. The response across cohorts 4-9 increased as patients progressed through the study to week 24, demonstrating the importance of stable, continuous long-term local steroids.